Uncategorized

Know Before You File: Using Patent Landscape Analysis to Drive Go/No-Go Decisions in Generic and Biosimilar Drug Development

Before You File: The Hidden Cost of Guessing in Generic & Biosimilar Development
In generic and biosimilar development, the most expensive decision is often the one made too early—before you’ve mapped the patent landscape with enough rigor to know …

Know Before You File: Using Patent Landscape Analysis to Drive Go/No-Go Decisions in Generic and Biosimilar Drug Development Read Post »

General Biotechnology

Own the Clock: How Pharma Companies Extract Maximum Value from Patent Term Extensions and Secondary Patents

Pharma doesn’t just “win” patents—it engineers time.
In a world where blockbuster drugs face relentless pressure from generics and biosimilars, the real competitive advantage often isn’t the original patent grant. It’s what comes after: the ability to …

Own the Clock: How Pharma Companies Extract Maximum Value from Patent Term Extensions and Secondary Patents Read Post »

Uncategorized

The Authorized Generic Playbook: Why Brands Launch Their Own Competition, Even if There is No Competition

Brands don’t “lose” to authorized generics—they design the loss.
That’s the counterintuitive takeaway from the authorized generic playbook: when a brand launches an authorized generic (AG), it’s not always because it’s confident the market will stay …

The Authorized Generic Playbook: Why Brands Launch Their Own Competition, Even if There is No Competition Read Post »

Biotechblog
Scroll to Top